Patent intelligence · US
US 10954293
Correctly folded etanercept in high purity and excellent yield
Correctly folded etanercept in high purity and excellent yield
Patent details — US 10954293
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 23, 2021
- Expiration
- Mar 18, 2041
- Applicant
- Coherus BioSciences, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61P
Quick answer
US 10954293 (Correctly folded etanercept in high purity and excellent yield) is held by Coherus BioSciences, Inc.. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Coherus BioSciences, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61P, A61P17/06, A61P19/02
More from Coherus BioSciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11667702
Stable aqueous formulations of aflibercept
granted -
US 11583584
Stable protein compositions and methods of their use
granted -
US 11576971
Method of filling a container with no headspace
granted -
US 11426446
Stable aqueous formulations of aflibercept
granted -
US 11400072
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
granted -
US 11396540
Methods for making recombinant proteins
granted -
US 11253508
PPARy agonist for treatment of progressive supranuclear palsy
granted -
US 11229702
High concentration formulations of adalimumab
granted
Related coverage
Frequently asked questions
What is US patent 10954293?
US 10954293 (Correctly folded etanercept in high purity and excellent yield) is held by Coherus BioSciences, Inc.. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10954293?
Coherus BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 73 pharmaceutical patents for this assignee.
When does US 10954293 expire?
Our index shows an expiration date of Mar 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.